EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Cardiovascular outcomes in patients with atrial fibrillation concomitantly treated with antiarrhythmic drugs and non-vitamin k antagonist oral anticoagulants

Victor Chien-Chia Wu iD, Chun-Li Wang iD, Yu-Chang Huang iD, Hui-Tzu Tu, Yu-Tung Huang iD, Chien-Hao Huang iD, Shao-Wei Chen iD, Chang-Fu Kuo iD, Kuo-Chun Hung iD, Shang-Hung Chang iD

Europace · 2023

DOI: 10.1093/europace/euad083 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Europace, 2023. Verfasst von Victor Chien-Chia Wu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Chang Gung Memorial Hospital, Linkou Medical Center, No. 5 Fuxing Street, Guishan District, Taoyuan City 33305, Taiwan. Hauptthemen laut MEDLINE: Atrial Fibrillation, Brain Ischemia, Stroke, Amiodarone. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Limited data compared antiarrhythmic drugs (AADs) with concomitant non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients, hence the aim of the study. Methods and results National health insurance database were retrieved during 2012–17 for study. We excluded patients not taking AADs, bradycardia, heart block, heart failure admission, mitral stenosis, prosthetic valve, incomplete demographic data, and follow-up <3 months. Outcomes were compared in Protocol 1, dronedarone vs. non-dronedarone; Protocol 2, dronedarone vs. amiodarone; and Protocol 3, dronedarone vs. propafenone. Outcomes were acute myocardial infarction (AMI), ischaemic stroke/systemic embolism, intracranial haemorrhage (ICH), major bleeding, cardiovascular death, all-cause mortality, and major adverse cardiovascular event (MACE) (including AMI, ischaemic stroke, and cardiovascular death). In Protocol 1, 2298 dronedarone users and 6984 non-dronedarone users (amiodarone = 4844; propafenone = 1914; flecainide = 75; sotalol = 61) were analysed. Dronedarone was associated with lower ICH (HR = 0.61, 95% CI = 0.38–0.99, P = 0.0436), cardiovascular death (HR = 0.24, 95% CI = 0.16–0.37, P < 0.0001), all-cause mortality (HR = 0.33, 95% CI = 0.27–0.42, P < 0.0001), and MACE (HR = 0.56, 95% CI = 0.45–0.70, P < 0.0001). In Protocol 2, 2231 dronedarone users and 6693 amiodarone users were analysed. Dronedarone was associated with significantly lower ICH (HR = 0.53, 95%=CI 0.33–0.84, P = 0.0078), cardiovascular death (HR = 0.20, 95% CI = 0.13–0.31, P < 0.0001), all-cause mortality (HR 0.27, 95% CI 0.22–0.34, P < 0.0001), and MACE (HR = 0.53, 95% CI = 0.43–0.66, P < 0.0001), compared with amiodarone. In Protocol 3, 812 dronedarone users and 2436 propafenone users were analysed. There were no differences between two drugs for primary and secondary outcomes.

Conclusion

The use of dronedarone with NOACs was associated with cardiovascular benefits in an Asian population, compared with non-dronedarone AADs and amiodarone.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationBrain IschemiaStrokeAmiodaroneIschemic StrokeHumansAnti-Arrhythmia AgentsPropafenoneAdministration, OralAnticoagulantsDronedarone

Stichwörter der Autor:innen

AmiodaroneAtrial fibrillationDronedaroneNon-vitamin K antagonist oral anticoagulantsPropafenone

Substanzen

Anti-Arrhythmia AgentsPropafenoneAnticoagulantsAmiodaroneDronedarone

Autor:innen und Institutionen

  • Division of Cardiology, Chang Gung Memorial Hospital, Linkou Medical Center, No. 5 Fuxing Street, Guishan District, Taoyuan City 33305, Taiwan.
  • Center for Big Data Analytics and Statistics, Chang Gung Memorial Hospital, Linkou Medical Center, No. 5 Fuxing Street, Guishan District, Taoyuan City 33305, Taiwan.
  • Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou Medical Center, Taoyuan City, Taiwan.
  • Department of Cardiothoracic and Vascular Surgery, Chang Gung Memorial Hospital, Linkou Medical Center, Taoyuan City, Taiwan.
  • Division of Rheumatology, Allergy and Immunology, Department of Internal Medicine, Chang Gung Memorial Hospital, Linkou Medical Center, Taoyuan City, Taiwan.
  • Division of Rheumatology, Orthopaedics and Dermatology, School of Medicine, University of Nottingham, Nottingham, UK.

ORCID-Profile: Victor Chien-Chia Wu, Chun-Li Wang, Yu-Chang Huang, Yu-Tung Huang, Chien-Hao Huang, Shao-Wei Chen, Chang-Fu Kuo, Kuo-Chun Hung, Shang-Hung Chang

Zitieren

APA

Wu, V. C., Wang, C. L., Huang, Y. C., Tu, H. T., Huang, Y. T., Huang, C. H., Chen, S. W., Kuo, C. F., Hung, K. C., & Chang, S. H. (2023). Cardiovascular outcomes in patients with atrial fibrillation concomitantly treated with antiarrhythmic drugs and non-vitamin k antagonist oral anticoagulants. Europace. https://doi.org/10.1093/europace/euad083

Vancouver

Wu VC, Wang CL, Huang YC, Tu HT, Huang YT, Huang CH, et al. Cardiovascular outcomes in patients with atrial fibrillation concomitantly treated with antiarrhythmic drugs and non-vitamin k antagonist oral anticoagulants. Europace. 2023. doi:10.1093/europace/euad083

BibTeX
@article{Wu2023,
  author = {Wu, Victor Chien-Chia and Wang, Chun-Li and Huang, Yu-Chang and Tu, Hui-Tzu and Huang, Yu-Tung and Huang, Chien-Hao and Chen, Shao-Wei and Kuo, Chang-Fu and Hung, Kuo-Chun and Chang, Shang-Hung},
  title = {Cardiovascular outcomes in patients with atrial fibrillation concomitantly treated with antiarrhythmic drugs and non-vitamin k antagonist oral anticoagulants},
  journal = {Europace},
  year = {2023},
  doi = {10.1093/europace/euad083}
}
Kostenlos starten →